A federal advisory committee voted 9 to 6 on Tuesday that a first-of-its-kind diabetes drug should not be approved for use because of safety concerns, including a possible increased risk of breast and bladder cancers.
The advisory committee to the Food and Drug Administration said that while the drug, dapagliflozin, had some attractive features as a treatment for type 2 diabetes, there were too
Technology Partners: MimirTech
Links:
[1] http://admin.indiaenvironmentportal.org.in/news/diabetes-drug-dapagliflozin-rejected-fda-panel
[2] http://admin.indiaenvironmentportal.org.in/category/author/andrew-pollack
[3] http://admin.indiaenvironmentportal.org.in/category/newspaper/new-york-times-new-york
[4] http://admin.indiaenvironmentportal.org.in/category/thesaurus/united-states-america-us
[5] http://admin.indiaenvironmentportal.org.in/category/thesaurus/health
[6] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drugs
[7] http://admin.indiaenvironmentportal.org.in/category/thesaurus/cancer
[8] http://admin.indiaenvironmentportal.org.in/category/thesaurus/health-effects
